Trial Profile
Phase 2 Study of Intermittent Oral Dosing of CM082 in Patients With wAMD: Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Jan 2022
Price :
$35
*
At a glance
- Drugs Vorolanib (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors AnewPharma
- 08 Jan 2020 Planned End Date changed from 8 Aug 2020 to 1 Jan 2022.
- 08 Jan 2020 Planned primary completion date changed from 8 Aug 2020 to 1 Jan 2022.
- 17 Sep 2019 Planned primary completion date changed from 8 Aug 2019 to 8 Aug 2020.